FY2026 Earnings Forecast for ALDX Issued By HC Wainwright

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued on Tuesday, November 10th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will earn ($0.27) per share for the year, up from their prior forecast of ($0.39). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at $0.01 EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.29 EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. Wall Street Zen cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aldeyra Therapeutics presently has an average rating of “Hold” and a consensus price target of $2.00.

Aldeyra Therapeutics Trading Up 3.5%

Shares of Aldeyra Therapeutics stock opened at $0.65 on Thursday. Aldeyra Therapeutics has a 12-month low of $0.53 and a 12-month high of $5.93. The company has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $2.14.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new position in shares of Aldeyra Therapeutics in the second quarter worth about $200,000. Two Sigma Securities LLC bought a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $70,000. Palo Alto Investors LP bought a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $331,660. Bank of America Corp DE acquired a new stake in shares of Aldeyra Therapeutics in the second quarter valued at approximately $72,000. Finally, Man Group plc acquired a new stake in shares of Aldeyra Therapeutics in the second quarter valued at approximately $325,000. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases. Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis.